Biological E Gets CDSCO Panel Nod to study safety of XBB 1.5-RBD Subunit Covid-19 Vaccine in 5-80 years old
New Delhi: The drug major Biological E has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase-III clinical trial of the SARS-CoV-2 (Covid-19) Vaccine (Variant XBB.1.5) This came after Biological E presented the Phase –III Clinical trial protocol titled “ A prospective […]